These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8817830)

  • 61. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
    [TBL] [Abstract][Full Text] [Related]  

  • 63. T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.
    Nardin E; Munesinghe YD; Moreno A; Clavijo P; Calle MC; Edelman R; Davis J; Herrington D; Nussenzweig RS
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():223-7. PubMed ID: 1364202
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Controlled human malaria infection.
    Spring M; Polhemus M; Ockenhouse C
    J Infect Dis; 2014 Jun; 209 Suppl 2():S40-5. PubMed ID: 24872394
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
    Horii T; Shirai H; Jie L; Ishii KJ; Palacpac NQ; Tougan T; Hato M; Ohta N; Bobogare A; Arakaki N; Matsumoto Y; Namazue J; Ishikawa T; Ueda S; Takahashi M
    Parasitol Int; 2010 Sep; 59(3):380-6. PubMed ID: 20493274
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population.
    Friedman-Klabanoff DJ; Travassos MA; Ifeonu OO; Agrawal S; Ouattara A; Pike A; Bailey JA; Adams M; Coulibaly D; Lyke KE; Laurens MB; Takala-Harrison S; Kouriba B; Kone AK; Doumbo OK; Patel JJ; Thera MA; Felgner PL; Tan JC; Plowe CV; Berry AA
    J Infect Dis; 2021 Jun; 223(11):1943-1947. PubMed ID: 32992328
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthetic Antigens Derived from
    Pratt-Riccio LR; De Souza Perce-Da-Silva D; Da Costa Lima-Junior J; Pratt Riccio EK; Ribeiro-Alves M; Santos F; Arruda M; Camus D; Druilhe P; Oliveira-Ferreira J; Daniel-Ribeiro CT; Banic DM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1581-1592. PubMed ID: 29016339
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Strong concordance between percent inhibition in oocyst and sporozoite intensities in a Plasmodium falciparum standard membrane-feeding assay.
    Miura K; Swihart BJ; Deng B; Zhou L; Pham TP; Diouf A; Fay MP; Long CA
    Parasit Vectors; 2019 May; 12(1):206. PubMed ID: 31060594
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
    Bergmann ES; Ballou RW; Krzych U
    Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials.
    Nardin E; Zavala F; Nussenzweig V; Nussenzweig RS
    Parassitologia; 1999 Sep; 41(1-3):397-402. PubMed ID: 10697892
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of human antibodies against Plasmodium falciparum antigens in blood meals of anopheline mosquitoes.
    Contreras CE; Beier JC
    J Am Mosq Control Assoc; 1992 Sep; 8(3):252-5. PubMed ID: 1402862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG
    Ubillos I; Jiménez A; Vidal M; Bowyer PW; Gaur D; Dutta S; Gamain B; Coppel R; Chauhan V; Lanar D; Chitnis C; Angov E; Beeson J; Cavanagh D; Campo JJ; Aguilar R; Dobaño C
    Malar J; 2018 Jun; 17(1):219. PubMed ID: 29859096
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Systems analysis of immune responses to attenuated P. falciparum malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity.
    Du Y; Hertoghs N; Duffy FJ; Carnes J; McDermott SM; Neal ML; Schwedhelm KV; McElrath MJ; De Rosa SC; Aitchison JD; Stuart KD
    PLoS Pathog; 2022 Feb; 18(2):e1010282. PubMed ID: 35108339
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults.
    Jongo S; Church LWP; Milando F; Qassim M; Schindler T; Rashid M; Tumbo A; Nyaulingo G; Bakari BM; Athuman Mbaga T; Mohamed L; Kassimu K; Simon BS; Mpina M; Zaidi I; Duffy PE; Swanson PA; Seder R; Herman JD; Mendu M; Zur Y; Alter G; Kc N; Riyahi P; Abebe Y; Murshedkar T; James ER; Billingsley PF; Sim BKL; Richie TL; Daubenberger C; Abdulla S; Hoffman SL
    J Clin Invest; 2024 Jan; 134(6):. PubMed ID: 38194272
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.
    Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R
    Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1.
    Roestenberg M; Walk J; van der Boor SC; Langenberg MCC; Hoogerwerf MA; Janse JJ; Manurung M; Yap XZ; García AF; Koopman JPR; Meij P; Wessels E; Teelen K; van Waardenburg YM; van de Vegte-Bolmer M; van Gemert GJ; Visser LG; van der Ven AJAM; de Mast Q; Natasha KC; Abebe Y; Murshedkar T; Billingsley PF; Richie TL; Sim BKL; Janse CJ; Hoffman SL; Khan SM; Sauerwein RW
    Sci Transl Med; 2020 May; 12(544):. PubMed ID: 32434847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.